Vaxxinity COVID-19 Vaccine Candidate Produces High Levels of Neutralizing Antibodies Against Omicron Oth,er Variants

 

• Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccines
   
• UB-612 elicits >3 times higher titers of neutralizing antibodies against Omicron variant than reported by an approved mRNA vaccine

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the Omicron variant of SARS-CoV-2 than an approved mRNA vaccine with boosters.

“The ability of these sera to neutralize Omicron at these high levels is extraordinary and unprecedented considering that Omicron has more than 30 potential immune evading mutations and deletions across its spike protein, 15 of which are in the RBD region where our UB-612 vaccine is directed. Such data show that UB-612 could potentially be a unique vaccine candidate that is highly effective at mobilizing the immune system against a broad range of both current and future SARS-CoV-2 variants,” said Farshad Guirakhoo, Ph.D., Chief Scientific Officer at Vaxxinity.

The studies were conducted by David Goldblatt, M.B. Ch.B., Ph.D., at University College London (UCL) and VisMederi, a Coalition for Epidemic Preparedness Innovations (CEPI)-centralized laboratory.

Sera from 92 participants from UB-612’s Phase 2 study including 8 placebos (randomized and tested blinded) and up to 36 participants in the Phase 1 study, half of the latter boosted with a third dose of UB-612, were used in these studies to analyze binding of IgG and neutralization against multiple Variants of Concern and Variants of Interest, including Omicron.

https://www.biospace.com/article/releases/vaxxinity-s-covid-19-vaccine-candidate-ub-612-produces-high-levels-of-neutralizing-antibodies-against-omicron-and-other-variants-of-concern/